Sharara AI et al. |
Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238584
|
Graham DY and Gisbert JP |
Letter: clarithromycin dose for H. pylori therapy remains unresolved. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238583
|
Kositchaiwat C et al. |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616168
|
Romero-Gómez M et al. |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616169
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Tepes B et al. |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421880
|
Calvet X et al. |
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421884
|
Cardenas VM et al. |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16393310
|
Kamada T et al. |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12869086
|
Lamouliatte H et al. |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535872
|
Gisbert JP and Calvet X |
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22129228
|
Miehlke S et al. |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535873
|
Neri M et al. |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535876
|
Lai KC et al. |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535877
|
Gisbert JP et al. |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10540045
|
Okudaira K et al. |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15710002
|
Sasaki A et al. |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823156
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Azuma T et al. |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10807427
|
Malfertheiner P et al. |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860399
|
Barth J and Hahne W |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849125
|
Qasim A and O'Morain CA |
Review article: treatment of Helicobacter pylori infection and factors influencing eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849124
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Yousfi MM et al. |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8853767
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Gisbert JP and Calvet X |
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21745241
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Elizalde JI et al. |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876713
|
Hawkey CJ et al. |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12694089
|
John Albert M et al. |
High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17059517
|
Villoria A et al. |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18644011
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Miyaji H et al. |
Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663841
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Leiper K et al. |
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18315579
|
Thung I et al. |
Review article: the global emergence of Helicobacter pylori antibiotic resistance. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26694080
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Graham DY et al. |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102946
|
Pilotto A and Malfertheiner P |
Review article: an approach to Helicobacter pylori infection in the elderly. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929385
|
Laine L et al. |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354200
|
Xiao SD et al. |
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11136281
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Zullo A et al. |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17539982
|
Nista EC et al. |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569121
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|
Savarino V et al. |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886045
|
Wang WH et al. |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886046
|
Chen PY et al. |
Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074519
|
Zamani M et al. |
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074507
|